Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Keysight Technologies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.96 (market cap $29.60B), while Keysight Technologies Inc trades at $352.45 (market cap $58.74B). The key difference: Keysight Technologies Inc is the larger of the two by market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | KEYS | |
|---|---|---|
Market Cap | $29.60B | $58.74B |
Sector | Health | Technology |
52-Week High | $491.22 | $373.34 |
52-Week Low | $205.48 | $158.51 |
Enterprise Value | $27.56B | $59.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
Keysight Technologies (KEYS) trades at $335.41, down 1.63% on the day, with a bullish technical outlook and strong analyst support. The stock exhibits robust fundamentals, including a 17.31% net income margin and consistent earnings beats, with Q1 2026 EPS of $2.87 surpassing the $2.32 estimate. Recent developments include new product launches and strategic collaborations, such as the certification of electromagnetic design software for Intel's latest processes (Business Wire, 2026-07-27).
The outlook for KEYS is positive, driven by earnings growth and innovation in test and measurement solutions. Key opportunities include expansion in 5G and cybersecurity markets, though risks involve high valuation multiples and competitive pressures. The consensus price target of $396.56 implies significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
